Repatha (Evolocumab) Regulatory Status: US, EU, Canada, and UK Approvals

How Evolocumab Works: The PCSK9 Mechanism

Evolocumab blocks PCSK9, a serine protease that degrades LDL receptors on the surface of hepatocytes. By binding circulating PCSK9 before it can attach to LDL receptors, evolocumab allows those receptors to recycle back to the cell surface and continue clearing LDL-C from the bloodstream. The result is a pronounced drop in serum LDL-C.

PCSK9 was first identified as a gain-of-function mutation linked to autosomal dominant hypercholesterolemia in 2003 by Abifadel et al. 1. Individuals carrying loss-of-function PCSK9 variants show lifelong low LDL-C and significantly reduced coronary heart disease risk. A landmark study by Cohen et al. (2006) demonstrated that heterozygous PCSK9 loss-of-function mutations were associated with a 28% reduction in mean LDL-C and an 88% reduction in coronary heart disease risk over a 15-year follow-up period 2. That genetic validation formed the rationale for therapeutic PCSK9 inhibition.

Evolocumab is a fully human IgG2 monoclonal antibody, meaning it contains no murine sequences. This design minimizes immunogenicity. In pooled phase III data, anti-drug antibody development occurred in fewer than 0.3% of treated patients 3. The drug is administered subcutaneously via a prefilled autoinjector (SureClick) or a manual prefilled syringe. Patients choose between 140 mg every two weeks or 420 mg (three consecutive 140 mg injections) once monthly, both regimens producing equivalent mean LDL-C reductions of approximately 59% when added to statin therapy 3.

United States: FDA Approval and Expanded Indications

The FDA granted evolocumab its initial approval on August 27, 2015, for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond diet and maximally tolerated statin therapy 4. A concurrent approval covered patients aged 13 years and older with homozygous familial hypercholesterolemia (HoFH).

The 2015 approval relied on data from the OSLER-1 and OSLER-2 open-label extension trials, where evolocumab reduced LDL-C by 61% from a median baseline of 120 mg/dL compared with standard therapy alone 3.

In December 2017, the FDA expanded the indication to include reduction of cardiovascular risk (myocardial infarction, stroke, and coronary revascularization) in adults with established ASCVD. This label expansion was based on the FOURIER trial 5. The updated prescribing information now explicitly references cardiovascular outcomes, not just LDL-C lowering. The FDA classified evolocumab as a specialty biologic, and it carries no boxed warning. Injection site reactions (3.2% vs. 3.0% placebo in FOURIER) represent the most common adverse event listed in the label.

European Union: EMA Marketing Authorization

The European Medicines Agency (EMA) authorized evolocumab on July 17, 2015, through its centralized procedure, granting a marketing authorization valid across all EU member states plus Iceland, Liechtenstein, and Norway 6. The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended approval based on the same phase III data package submitted to the FDA.

Approved EU indications include primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia in adults, as an adjunct to diet in combination with a statin or other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated. A separate indication covers HoFH in patients aged 12 years and older.

The EMA's European Public Assessment Report noted that evolocumab produced consistent LDL-C reductions across European subgroups in the RUTHERFORD-2 (HeFH) and TESLA Part B (HoFH) trials 6. Mean LDL-C reduction in RUTHERFORD-2 was 59.2% at the 140 mg biweekly dose and 61.3% at the 420 mg monthly dose versus placebo at 12 weeks 7. Following publication of FOURIER data, the EMA updated the product information in 2018 to reflect the cardiovascular outcomes benefit. The European authorization has been renewed and remains active with no restrictions on its current status.

Canada: Health Canada Authorization

Health Canada approved evolocumab on September 10, 2015, making it the first PCSK9 inhibitor authorized in Canada 8. The Canadian product monograph mirrors the US label's indications: HeFH, HoFH (patients aged 13 and older), and primary hyperlipidemia in adults requiring additional LDL-C lowering.

The Canadian Drug Expert Committee (CDEC) at the Canadian Agency for Drugs and Technologies in Health (CADTH) issued a conditional recommendation for reimbursement in 2016, restricted to patients with HeFH who had failed maximally tolerated statin therapy plus ezetimibe and maintained LDL-C above 2.59 mmol/L (100 mg/dL). CDEC noted that while the LDL-C reduction was "clinically meaningful," outcomes data were immature at that time.

Following the FOURIER publication, the pan-Canadian Pharmaceutical Alliance (pCPA) renegotiated pricing. As of 2024, most provincial drug plans in Canada now cover evolocumab for patients with ASCVD on maximally tolerated statins, though prior authorization requirements vary by province. Ontario's Exceptional Access Program (EAP), for example, requires documentation of LDL-C above 1.8 mmol/L (approximately 70 mg/dL) despite optimal background therapy before approving coverage.

United Kingdom: MHRA and NICE Guidance

In the UK, evolocumab was initially available through the EMA's centralized marketing authorization. Following Brexit on January 1, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) converted the existing EU authorization into a Great Britain marketing authorization under the Northern Ireland Protocol provisions 9.

The National Institute for Health and Care Excellence (NICE) published Technology Appraisal 394 (TA394) in June 2016, recommending evolocumab only for patients with primary non-familial hypercholesterolemia or mixed dyslipidemia whose LDL-C concentration remained persistently above 4.0 mmol/L (155 mg/dL) despite maximal tolerated lipid-lowering therapy, or for HeFH patients with LDL-C above 3.5 mmol/L (135 mg/dL) on maximal therapy 10. NICE updated the guidance in 2023 to incorporate cardiovascular outcomes evidence from FOURIER and align thresholds with the NHS Long Term Plan's lipid management targets.

NICE's assessment noted: "Evolocumab produces substantial reductions in LDL cholesterol and, based on the FOURIER trial, reduces the risk of cardiovascular events when added to optimised statin therapy" 10. Access in clinical practice, however, remains subject to regional commissioning decisions within NHS England's Integrated Care Boards.

The FOURIER Trial: Cardiovascular Outcomes Evidence

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) remains the largest and most influential outcomes trial for evolocumab. Published in the New England Journal of Medicine in March 2017, this multinational, randomized, double-blind, placebo-controlled trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease who were already receiving statin therapy 5.

At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative to placebo (hazard ratio 0.85; 95% CI, 0.79 to 0.92; P<0.001). The key secondary endpoint (cardiovascular death, MI, or stroke) showed a 20% relative risk reduction (HR 0.80; 95% CI, 0.73 to 0.88; P<0.001) 5.

Median achieved LDL-C was 30 mg/dL (0.78 mmol/L) in the evolocumab group versus 92 mg/dL (2.38 mmol/L) with placebo. The trial found no excess of neurocognitive adverse events, new-onset diabetes, or myalgia in the evolocumab arm. FOURIER principal investigator Dr. Marc Sabatine stated: "The results establish that inhibiting PCSK9 with evolocumab on a background of statin therapy lowers LDL cholesterol to a median of 30 mg/dL and reduces the risk of cardiovascular events" 5.

Longer-term follow-up data from FOURIER-OLE (open-label extension) demonstrated that the cardiovascular benefit continued to accrue over a median of 5 years, with a 15% relative reduction in cardiovascular death (nominal P=0.01) and no new safety signals with prolonged exposure at very low LDL-C levels 11.

Guideline Positioning Across Regions

Major cardiovascular societies have incorporated PCSK9 inhibitors into their lipid management algorithms. The 2018 AHA/ACC Multisociety Cholesterol Guideline recommends consideration of a PCSK9 inhibitor for patients with clinical ASCVD at very high risk whose LDL-C remains at or above 70 mg/dL (1.8 mmol/L) on maximally tolerated statin plus ezetimibe 12. The guideline defines "very high risk" using a specific set of clinical criteria including history of multiple major ASCVD events or one major event plus multiple high-risk conditions.

The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) 2019 guidelines set more aggressive LDL-C targets: below 55 mg/dL (1.4 mmol/L) for very high-risk patients and below 70 mg/dL (1.8 mmol/L) for high-risk patients. The guidelines state that "if the goals are not achieved with the maximum tolerated dose of statin and ezetimibe, combination with a PCSK9 inhibitor is recommended" (Class I, Level A) 13. This recommendation is stronger than the AHA/ACC position, reflecting the ESC's emphasis on lower absolute LDL-C targets.

The Canadian Cardiovascular Society (CCS) 2021 lipid guidelines similarly recommend PCSK9 inhibitors for statin-treated patients with ASCVD who do not reach target LDL-C on maximally tolerated statin plus ezetimibe 14. NICE's updated lipid pathway for the UK aligns with ESC thresholds for high-risk secondary prevention.

Prescribing Considerations and Access Barriers

Cost remains the most significant barrier to evolocumab uptake globally. Amgen reduced the US list price by approximately 60% in 2018 (from roughly $14,100 to $5,850 per year) following an Institute for Clinical and Economic Review (ICER) analysis that set a cost-effectiveness threshold of $2,300 to $3,400 annually 15. Despite the price cut, prior authorization requirements persist across most US commercial and Medicare Part D plans. Step therapy typically mandates failure of maximally tolerated statin plus ezetimibe, with documented LDL-C above a plan-specific threshold (usually 70 mg/dL for ASCVD patients), before approval.

Storage requires refrigeration at 2 to 8 degrees Celsius, though the prefilled autoinjector may be kept at room temperature (up to 25 degrees Celsius) for up to 30 days. Patients self-inject in the abdomen, thigh, or upper arm. No dose adjustment is needed for renal impairment, hepatic impairment, age, sex, or race based on pharmacokinetic analyses from the phase III program 4.

Biosimilar development for evolocumab is in early stages as of 2026, with the original biologic exclusivity in the US set under the Biologics Price Competition and Innovation Act's 12-year reference product exclusivity period (expiring 2027). EU data protection provisions provide 8 years of data exclusivity plus 2 years of market protection from the date of initial authorization.